Published in Int J Cancer on September 04, 1997
Beta 1-integrins regulate the formation and adhesion of ovarian carcinoma multicellular spheroids. Am J Pathol (2001) 1.69
Ovarian carcinoma spheroids disaggregate on type I collagen and invade live human mesothelial cell monolayers. Clin Exp Metastasis (2004) 1.60
Disaggregation and invasion of ovarian carcinoma ascites spheroids. J Transl Med (2006) 1.43
Models of ovarian cancer metastasis: Murine models. Drug Discov Today Dis Models (2006) 0.92
Versican regulates metastasis of epithelial ovarian carcinoma cells and spheroids. J Ovarian Res (2014) 0.83
Targeted alpha therapy approach to the management of pancreatic cancer. Cancers (Basel) (2011) 0.80
Detection of high molecular weight DNA fragments characteristic of early stage apoptosis in cerebellar granule cells exposed to glutamate. Exp Brain Res (2000) 0.76
Mcl-1 is overexpressed in multiple myeloma and associated with relapse and shorter survival. Leukemia (2005) 2.30
Rituximab in CD20 positive multiple myeloma. Leukemia (2007) 2.11
Reproducible obtaining of human myeloma cell lines as a model for tumor stem cell study in human multiple myeloma. Blood (1994) 2.10
Reactive plasmacytoses are expansions of plasmablasts retaining the capacity to differentiate into plasma cells. Blood (1999) 1.65
Brown fat in breast cancer patients: analysis of serial (18)F-FDG PET/CT scans. Eur J Nucl Med Mol Imaging (2006) 1.53
Ploidy, as detected by fluorescence in situ hybridization, defines different subgroups in multiple myeloma. Leukemia (2005) 1.49
Evaluation of indium-111-labeled antifibrin monoclonal antibody for the diagnosis of venous thrombotic disease. J Nucl Med (1991) 1.39
Expression of CD28 and CD40 in human myeloma cells: a comparative study with normal plasma cells. Blood (1994) 1.37
Randomized controlled trial of a monoclonal antibody against the interleukin-2 receptor (33B3.1) as compared with rabbit antithymocyte globulin for prophylaxis against rejection of renal allografts. N Engl J Med (1990) 1.35
Screening for multiple endocrine neoplasia type 2a with DNA-polymorphism analysis. N Engl J Med (1989) 1.32
Immunoscintigraphy of colon carcinoma. J Nucl Med (1984) 1.31
The absence of CD56 (NCAM) on malignant plasma cells is a hallmark of plasma cell leukemia and of a special subset of multiple myeloma. Leukemia (1998) 1.22
A dose-controlled study of 153Sm-ethylenediaminetetramethylenephosphonate (EDTMP) in the treatment of patients with painful bone metastases. Eur J Cancer (1997) 1.20
Tumor localization in patients by radiolabeled monoclonal antibodies against colon carcinoma. Cancer Res (1983) 1.16
Zoledronate is a potent inhibitor of myeloma cell growth and secretion of IL-6 and MMP-1 by the tumoral environment. J Bone Miner Res (1999) 1.04
CD33 is expressed on plasma cells of a significant number of myeloma patients, and may represent a therapeutic target. Leukemia (2005) 1.02
Differential expression of Bcl-2 in human plasma cell disorders according to proliferation status and malignancy. Leukemia (1999) 1.00
Polylysine-Gd-DTPAn and polylysine-Gd-DOTAn coupled to anti-CEA F(ab')2 fragments as potential immunocontrast agents. Relaxometry, biodistribution, and magnetic resonance imaging in nude mice grafted with human colorectal carcinoma. Invest Radiol (1998) 0.99
Two-step targeting of xenografted colon carcinoma using a bispecific antibody and 188Re-labeled bivalent hapten: biodistribution and dosimetry studies. J Nucl Med (2001) 0.97
Comparison of iodobenzylguanidine imaging with computed tomography in locating pheochromocytoma. J Clin Endocrinol Metab (1985) 0.96
Pretargeting with the affinity enhancement system for radioimmunotherapy. Cancer Biother Radiopharm (1999) 0.95
Farnesyl transferase inhibitor R115777 induces apoptosis of human myeloma cells. Leukemia (2002) 0.93
Minimally differentiated erythroleukaemia (AML M6 'variant'): a rare subset of AML distinct from AML M6. Groupe Français d'Hématologie Cellulaire. Br J Haematol (1995) 0.92
Radioimmunodetection of medullary thyroid carcinoma using indium-111 bivalent hapten and anti-CEA x anti-DTPA-indium bispecific antibody. J Nucl Med (1998) 0.91
Treatment of bone metastases of prostate cancer with strontium-89 chloride: efficacy in relation to the degree of bone involvement. Eur J Nucl Med (2000) 0.90
Radioimmunotherapy in medullary thyroid cancer using bispecific antibody and iodine 131-labeled bivalent hapten: preliminary results of a phase I/II clinical trial. Clin Cancer Res (1999) 0.90
Development of a method for direct quantification of cytomegalovirus antigenemia by flow cytometry. J Clin Microbiol (1997) 0.90
Use of multi-cell spheroids of ovarian carcinoma as an intraperitoneal radio-immunotherapy model: uptake, retention kinetics and dosimetric evaluation. Int J Cancer (1992) 0.89
Simultaneous study of five candidate target antigens (CD20, CD22, CD33, CD52, HER2) for antibody-based immunotherapy in B-ALL: a monocentric study of 44 cases. Leukemia (2008) 0.89
Absorbed doses for internal radiotherapy from 22 beta-emitting radionuclides: beta dosimetry of small spheres. Phys Med Biol (1994) 0.88
High frequency of bone/bone marrow involvement in advanced medullary thyroid cancer. J Clin Endocrinol Metab (2004) 0.88
Staphylococcus aureus, T-cell repertoire, and Wegener's granulomatosis. Joint Bone Spine (2001) 0.86
Bispecific antibody and iodine-131-labeled bivalent hapten dosimetry in patients with medullary thyroid or small-cell lung cancer. J Nucl Med (1996) 0.86
Does the corticoadrenal adenoma with "pre-Cushing's syndrome" exist? J Nucl Med (1981) 0.85
Radioimmunotherapy of small cell lung carcinoma with the two-step method using a bispecific anti-carcinoembryonic antigen/anti-diethylenetriaminepentaacetic acid (DTPA) antibody and iodine-131 Di-DTPA hapten: results of a phase I/II trial. Clin Cancer Res (1999) 0.85
Radioimmunodetection of medullary thyroid cancer using a bispecific anti-CEA/anti-indium-DTPA antibody and an indium-111-labeled DTPA dimer. J Nucl Med (1993) 0.85
Gd-25 DTPA-MAb, a potential NMR contrast agent for MRI in the xenografted nude mouse: preliminary studies. Int J Cancer Suppl (1988) 0.85
Sequential use of paraformaldehyde and methanol as optimal conditions for the direct quantification of ZEBRA and rta antigens by flow cytometry. Clin Diagn Lab Immunol (2000) 0.85
Reactive plasmacytoses can mimick plasma cell leukemia: therapeutical implications. Leuk Lymphoma (2007) 0.84
Radiation-induced apoptosis in human tumor cell lines: adaptive response and split-dose effect. Int J Cancer (1998) 0.84
Variable region gene segments of nine monoclonal antibodies specific to disialogangliosides (GD2, GD3) and their O-acetylated derivatives. Hybridoma (1997) 0.83
The respective roles of gallium 67 citrate scanning and diagnostic ultrasound in detecting suppurations in renal allograft recipients. Pathol Biol (Paris) (1980) 0.83
Bispecific monoclonal antibody-mediated targeting of an indium-111-labeled DTPA dimer to primary colorectal tumors: pharmacokinetics, biodistribution, scintigraphy and immune response. J Nucl Med (1993) 0.82
Toxicity and efficacy of radioimmunotherapy in carcinoembryonic antigen-producing medullary thyroid cancer xenograft: comparison of iodine 131-labeled F(ab')2 and pretargeted bivalent hapten and evaluation of repeated injections. Clin Cancer Res (1999) 0.82
Use of serial carcinoembryonic antigen assays in detecting relapses in breast cancer involving high risk of metastasis. Eur J Cancer (1981) 0.82
Feasibility study of radioimmunoguided surgery of colorectal carcinomas using indium-111 CEA-specific monoclonal antibody. Eur J Nucl Med (1990) 0.82
Detection of t(11;14) using interphase molecular cytogenetics in mantle cell lymphoma and atypical chronic lymphocytic leukemia. Genes Chromosomes Cancer (1998) 0.82
Effects of loratadine (SCH 29851) in suppression of histamine-induced skin wheals. Ann Allergy (1988) 0.82
Famciclovir for ophthalmic zoster: a randomised aciclovir controlled study. Br J Ophthalmol (2001) 0.82
CD11a-CD18 and CD102 interactions mediate human myeloma cell growth arrest induced by CD40 stimulation. Cancer Res (1996) 0.81
DNA or cell kinetics flow cytometry analysis of 33 small gastrointestinal cancers treated by photodynamic therapy. Cancer (1994) 0.81
A correlative study of the measurement of human cardiac output as determined by thermodilution and radiocardiography. Eur J Nucl Med (1978) 0.81
Pharmacokinetics and biodistribution of samarium-153-labelled OC125 antibody coupled to CITCDTPA in a xenograft model of ovarian cancer. Eur J Nucl Med (1996) 0.81
Pretargeted radioimmunotherapy in the treatment of metastatic medullary thyroid cancer. Curr Oncol (2009) 0.81
Biodistribution of anti-CEA F(ab')2 fragments conjugated with chelating polymers: influence of conjugate electron charge on tumor uptake and blood clearance. Nucl Med Biol (1993) 0.81
Current status and perspectives in alpha radioimmunotherapy. Q J Nucl Med Mol Imaging (2006) 0.81
Autocrine insulin-like growth factor 1 and stem cell factor but not interleukin 6 support self-renewal of human myeloma cells. Blood Cancer J (2013) 0.80
Biodistribution of indium-111-labeled OC 125 monoclonal antibody after intraperitoneal injection in nude mice intraperitoneally grafted with ovarian carcinoma. Cancer Res (1989) 0.80
Biodistribution and dosimetric study in medullary thyroid cancer xenograft using bispecific antibody and iodine-125-labeled bivalent hapten. J Nucl Med (1998) 0.80
Selection of Epstein-Barr virus specific cytotoxic T lymphocytes can be performed with B lymphoblastoid cell lines created in serum-free media. Clin Exp Immunol (2006) 0.80
G-CSF alone mobilizes sufficient peripheral blood CD34+ cells for positive selection in newly diagnosed patients with myeloma. Br J Haematol (1996) 0.79
A one-step RT-PCR and a flow cytometry method as two specific tools for direct evaluation of human herpesvirus-6 replication. J Virol Methods (2003) 0.79
CD130 rather than CD126 expression is associated with disease activity in multiple myeloma. Br J Haematol (1999) 0.79
A phase II study of intraperitoneal radioimmunotherapy with iodine-131-labeled monoclonal antibody OC-125 in patients with residual ovarian carcinoma. Clin Cancer Res (1999) 0.79
[Difficulties of the X-ray computed tomographic diagnosis of pelvic tumor recurrence: comparison with other medical imaging techniques (ultrasonography, immunoscintigraphy)]. Ann Radiol (Paris) (1988) 0.79
Immunoscintigraphy using 111In-labeled F(ab')2 fragments of anticarcinoembryonic antigen monoclonal antibody for detecting recurrences of medullary thyroid carcinoma. J Clin Endocrinol Metab (1992) 0.79
Bispecific antibody and bivalent hapten radioimmunotherapy in CEA-producing medullary thyroid cancer xenograft. J Nucl Med (1999) 0.79
Immunohistochemical antigenic expression and in vivo tumor uptake of monoclonal antibodies with specificity for tumors of the gastrointestinal tract. Cancer Res (1986) 0.79
In vitro therapeutic targeting of neuroblastomas using 125I-labelled meta-iodobenzylguanidine. Int J Cancer (1990) 0.79
Pharmacokinetic study of radiolabeled anti-colorectal carcinoma monoclonal antibodies in tumor-bearing nude mice. Eur J Nucl Med (1985) 0.78
Reactive plasmacytoses, a model for studying the biology of human plasma cell progenitors and precursors. Hematol J (2000) 0.78
Radiolabeling and targeting of lipidic nanocapsules for applications in radioimmunotherapy. Q J Nucl Med Mol Imaging (2007) 0.78
Ovarian cancer management. Practice guidelines for nuclear physicians. Q J Nucl Med Mol Imaging (2004) 0.78
Selective modification of NMR relaxation time in human colorectal carcinoma by using gadolinium-diethylenetriaminepentaacetic acid conjugated with monoclonal antibody 19-9. Proc Natl Acad Sci U S A (1986) 0.78
Effects in vitro of two marine substances, chlorolissoclimide and dichlorolissoclimide, on a non-small-cell bronchopulmonary carcinoma line (NSCLC-N6). Anticancer Drug Des (1992) 0.78
Effect of the inducers of cellular differentiation and of ionizing radiation on thymus lymphocytes: chromatin degradation and programmed cell death. Int J Radiat Biol Relat Stud Phys Chem Med (1988) 0.78
[Localization of pheochromocytomas by scintigraphy with meta-iodobenzyl guanidine. Comparison with computed x-ray tomography]. Presse Med (1984) 0.78
Detection of lung and bone infection with anti-granulocyte monoclonal antibody BW 250/183 radiolabelled with 99Tcm. Nucl Med Commun (1993) 0.78
Immunohistochemical study of ovarian tumors using the OC 125 monoclonal antibody as a basis for potential in vivo and in vitro applications. J Nucl Med Allied Sci (1986) 0.78
Immunophenotypic characterization of acute leukemias and chronic lymphoproliferative disorders: practical recommendations and classifications. Hematol Cell Ther (1996) 0.78
Radiation-induced apoptosis in human myeloma cell line increases BCL-2/BAX dimer formation and does not result in BAX/BAX homodimerization. Int J Cancer (2001) 0.78
Childhood B-cell acute lymphoblastic leukemia with FAB-L1 morphology and a t(9;11) translocation involving the MLL gene. Hematol Cell Ther (1996) 0.78
Influence of epidermal growth factor on photodynamic therapy of glioblastoma cells in vitro. Res Exp Med (Berl) (1997) 0.77
Validation of 213Bi-alpha radioimmunotherapy for multiple myeloma. Clin Cancer Res (1999) 0.77
Effects of bistramide A on a non-small-cell bronchial carcinoma line. Cancer Chemother Pharmacol (1991) 0.77
Comparison of technetium-99m aerosol and krypton-81m in ventilation studies for the diagnosis of pulmonary embolism. Nucl Med Commun (1990) 0.77
Synthesis of new bivalent peptides for applications in the Affinity Enhancement System. Bioconjug Chem (2005) 0.77
Induction of anaesthesia by propofol and hepatic blood flow in the rabbit. Clin Physiol (1995) 0.77
Usefulness of imaging ovarian cancer recurrence with In-111-labeled monoclonal antibody (OC 125) specific for CA 125 antigen. The INSERM Research Network (Nantes, Rennes, Reims, Vuillejuif, Saclay. Ann Oncol (1993) 0.77
Bistramide A-induced irreversible arrest of cell proliferation in a non-small-cell bronchopulmonary carcinoma is similar to induction of terminal maturation. Biol Cell (1993) 0.76
Two-step targeting and dosimetry for small cell lung cancer xenograft with anti-NCAM/antihistamine bispecific antibody and radioiodinated bivalent hapten. J Nucl Med (1999) 0.76
Immunotherapy of gastrointestinal cancer with monoclonal antibodies. Med Oncol Tumor Pharmacother (1986) 0.76
IgG-secreting lymphoplasmacytoid leukaemia: a B-cell disorder with extensively mutated VH genes undergoing Ig isotype-switching frequently associated with trisomy 12. Br J Haematol (2000) 0.76
Rhenium-188-labeled anti-neural cell adhesion molecule antibodies with 2-iminothiolane modification for targeting small-cell lung cancer. Ann Nucl Med (2000) 0.76
CD72 is constantly expressed in chronic lymphocytic leukemia and other B-cell lymphoproliferative disorders. Leuk Res (1994) 0.76